ClinicalTrials.gg
CompletedNCT02283268Updated May 19, 2021Results posted

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

A Phase 3 interventional study of Recombinant von Willebrand Factor (rVWF) in Von Willebrand Disease, sponsored by Baxalta now part of Shire. Completed at 34 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in von Willebrand Diseases by Takeda — 3 open to participants now, 3 under way, 2 of them phase 3. von Willebrand Diseases · Takeda.

Started
2015
the only one that year
Phase 3
7 of 13
2 open now
Registered
3rd of 13
by date

Among the 13 studies in von Willebrand Diseases by Takeda, this one is the only one that started in 2015, is one of 7 in phase 3, and was the 3rd registered.

von Willebrand Diseases

96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.

Browse von Willebrand Diseases studies →

Open to participants now

3 of the 13 studies in von Willebrand Diseases by Takeda are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 23 von Willebrand Diseases studies recruiting now, 15 (65%) set no upper age limit and 8 (35%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in von Willebrand Diseases by Takeda, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy and safety of recombinant von Willebrand factor (rVWF) with or without ADVATE in major and minor elective surgical procedures in adult patients with hereditary severe von Willebrand disease (VWD).

03

Conditions studied

  • Von Willebrand Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of severe von Willebrand disease (VWD) as listed below and elective surgical procedure planned

    1. Type 1 (Von Willebrand factor : Ristocetin cofactor activity (VWF:RCo) \<20 IU/dL), or
    2. Type 2A (as verified by multimer pattern), Type 2B (as diagnosed by genotype), Type 2N (FVIII:C\<10% and historically documented genetics), Type 2M, or
    3. Type 3 (Von Willebrand factor antigen (VWF:Ag) ≤ 3 IU/dL)
  • VWD with a history of requiring substitution therapy with von Willebrand factor (VWF) concentrate to control bleeding
  • If type 3 VWD (VWF Antigen /VWF:Ag ≤ 3 IU/dL), participant has a medical history of at least 20 exposure days to VWF/FVIII coagulation factor concentrates (including cryoprecipitate or fresh frozen plasma)
  • If type 1 or type 2 VWD, participant has a medical history of 5 exposure days or a past major surgery requiring VWF/FVIII coagulation factor concentrates (including cryoprecipitate or fresh frozen plasma)
  • Participant is at least 18 years of age
  • If female of , participant presents with a negative pregnancy test
  • If applicable, participant agrees to employ adequate measures for the duration of the study
  • Participant is willing and able to comply with the requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of pseudo VWD or another hereditary or acquired coagulation disorder (eg, qualitative and quantitative disorders or elevated [PT] / international normalized ratio [INR] > 1.4)
  • History or presence of a VWF inhibitor at screening
  • History or presence of a factor VIII (FVIII) inhibitor with a titer ≥ 0.4 BU (Nijmegen-modified Bethesda assay ) or ≥ 0.6 BU (by Bethesda assay)
  • Known to any of the components of the study drugs, such as to mouse or hamster proteins
  • Medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, mild asthma, food allergies or animal allergies
  • Medical history of a thromboembolic event
  • positive with an absolute \< 200/mm3
  • Platelet count \< 100,000/mL
  • Diagnosis of significant liver disease, as evidenced by, but not limited to, any of the following: serum (ALT) 5 times the ; hypoalbuminemia; portal vein hypertension (eg. presence of otherwise unexplained splenomegaly, history of esophageal varices) or liver cirrhosis classified as Child B or C
  • Diagnosis of renal disease, with a serum creatinine level ≥ 2 .5mg/dL
  • Participant has been treated with an immunomodulatory drug, excluding topical treatment (eg, ointments, nasal sprays), within 30 days prior to signing the
  • Participant is pregnant or lactating at the time informed content is obtained
  • Participant has participated in another clinical study involving an product (IP), other than rVWF with or without ADVATE, or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study. However, eligible patients participating in the rVWF Prophylaxis Study (071301) may be enrolled.
  • Progressive fatal disease and/or of less than 3 months
  • Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures
  • Participant suffers from a mental condition rendering him/her unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude
  • Participant is in prison or compulsory detention by regulatory and/or juridical order
  • Participant is a member of the study team conducting this study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie, children, partner/spouse, siblings, parents) as well as employees.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Recombinant von Willebrand Factor (rVWF)

    Surgery participants treated with Recombinant von Willebrand Factor (rVWF)

    Biological: Recombinant von Willebrand Factor (rVWF)

Interventions

  • rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.

06

What researchers measure

Primary outcomes

  1. Overall Hemostatic Efficacy as Assessed by the Investigator (Hemophilia Physician)

    Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intra-, and postoperative hemostasis achieved with rVWF with our without ADVATE was as good or better than that expected for the type of surgical procedure performed in a hemostatically normal subject. Good: Intra-, and postoperative hemostasis achieved with rVWF with or without ADVATE was probably as good as that expected for the type of surgical procedure performed in a hemostatically normal subject. Moderate: Intra-, and postoperative hemostasis with rVWF with or without ADVATE was clearly less than optimal for the type of procedure performed but was maintained without the need to change the rVWF concentrate. None: Participant experienced uncontrolled bleeding that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of rVWF concentrate.

    Time frame: 24 hours after last peri-operative infusion or at completion of Day 14 (± 2 days) visit, whichever occurs earlier

Secondary outcomes

  1. Intraoperative Actual Versus Predicted Blood Loss as Assessed by the Operating Surgeon

    The predicted blood loss will be estimated preoperatively by the operating surgeon based on a hemostatically normal individual of the same sex, age, stature and co-morbidities as the participant. The actual blood loss will be assessed consisting of the estimated blood loss, including into swabs, towels and suction during the procedure, per the anesthesiologist's record.

    Time frame: Day 0 (at completion of surgery)

  2. Intraoperative Actual Blood Loss Relative to Predicted Blood Loss

    Actual blood loss relative to predicted blood loss will be calculated as \[Actual Blood loss (mL)\] divided by \[Predicted Blood Loss (mL) multiplied by 100.

    Time frame: Day 0 (at completion of surgery)

  3. Intraoperative Actual Versus Predicted Blood Loss Score as Assessed by the Operating Surgeon

    Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intraoperative blood loss was less than or equal to the maximum blood loss expected for the type of procedure performed in a hemostatically normal subject (≤ 100%). Good: Intraoperative blood loss was up to 50% more than the maximum expected blood loss for the type of procedure performed in a hemostatically normal subject (101-150%) Moderate: Intraoperative blood loss was more than 50% of the maximum expected blood loss for the type of procedure performed in a hemostatically normal subject (\>150%). None: Uncontrolled hemorrhage that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of clotting factor replacement regimen.

    Time frame: Day 0 (at completion of surgery)

  4. Intraoperative Hemostatic Efficacy Score as Assessed by the Operating Surgeon

    Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intraoperative hemostasis achieved with rVWF with our without ADVATE was as good or better than that expected for the type of surgical procedure performed in a hemostatically normal subject. Good: Intraoperative hemostasis achieved with rVWF with or without ADVATE was probably as good as that expected for the type of surgical procedure performed in a hemostatically normal subject. Moderate: Intraoperative hemostasis with rVWF with or without ADVATE was clearly less than optimal for the type of procedure performed but was maintained without the need to change the rVWF concentrate. None: Participant experienced uncontrolled bleeding that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of rVWF concentrate.

    Time frame: Day 0 (at completion of surgery)

  5. Daily Intra- and Postoperative Weight-adjusted Dose of rVWF With or Without ADVATE

    Time frame: Daily, from day of surgery through postoperative Day 14 (± 2 days)

  6. Occurrence of Adverse Events

    Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated.

    Time frame: From first infusion of investigational product through study completion (ie, 14 (± 2) days post surgery)

  7. Occurrence of Thrombotic Events

    Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated for thrombotic events.

    Time frame: From first infusion of investigational product through study completion (ie, 14 (± 2) days post surgery)

  8. Occurrence of Severe Allergic Reactions (eg, Anaphylaxis)

    Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated for severe allergic reactions.

    Time frame: From first infusion of investigational product through study completion (ie, 14 (± 2) days post surgery)

  9. Number of Participants Who Developed Inhibitory and Total Binding Antibodies to Von Willebrand Factor (VWF) and Inhibitory Antibodies to Factor VIII (FVIII)

    Participants were treated with recombinant van Willebrand Factor (rVWF) with or without ADVATE.

    Time frame: Testing occurred throughout the study at screening, prior PK infusion, pre-surgery, post surgery in case of excessive bleeding or unexplained bleeding, at postoperative day 7 and at study completion visit (ie. 14 (± 2) days post surgery).

  10. Number of Participants Who Developed Antibodies to Chinese Hamster Ovary (CHO) Proteins, Mouse Immunoglobulin G (IgG) or Recombinant Furin (rFurin)

    Participants were treated with recombinant van Willebrand Factor (rVWF) with or without ADVATE.

    Time frame: Testing occurred throughout the study at screening, prior PK infusion, pre-surgery, post surgery in case of excessive bleeding or unexplained bleeding, at postoperative day 7 and at study completion visit (ie. 14 (± 2) days post surgery).

  11. Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Post-infusion (AUC 0-72 h/Dose)

    This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. The area under the plasma concentration/time curve from 0 to 72 hours post-infusion will be computed using the linear trapezoidal rule. For the calculation of AUC(0-72h) the levels at 72 hours will be linearly interpolated/extrapolated from the 2 nearest sampling time points. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac), FVIII Coagulation Activity (FVIII:C)

    Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.

  12. Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC 0-∞ /Dose)

    This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. The area under the plasma concentration/time curve from time 0 to infinity and the area under the first moment curve from time 0 to infinity will be calculated as the sum of AUC or AUMC from time 0 to the time of last quantifiable concentration plus a tail area correction calculated as Ct/λz and Ct/λz(t+1/λz), respectively, where Ct is the last quantifiable concentration, t is the time of last quantifiable concentration and λz is the terminal or disposition rate constant. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac), FVIII Coagulation Activity (FVIII:C)

    Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.

  13. Pharmacokinetics: Mean Residence Time (MRT)

    This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Mean residence time will be calculated as area under the first moment curve from time 0 to infinity divided by the area under the curve time 0 to infinity minus T/2 where T is the duration of the infusion. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)

    Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.

  14. Pharmacokinetics: Clearance (CL)

    This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Clearance will be calculated as dose (IU/kg) divided by the area under the curve time 0 to infinity. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)

    Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.

  15. Pharmacokinetics: Incremental Recovery (IR)

    This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Incremental recovery will be calculated as (Cmax minus Cpreinfusion) divided by the dose (IU/kg) where kg refers to the body weight at the time of dosing and Cmax is the observed maximum concentration before correction for pre-infusion values. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)

    Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.

  16. Pharmacokinetics: Elimination Phase Half-life (T1/2)

    This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Terminal or disposition half-life (T1/2) will be calculated as ln2/λz where λz is the terminal elimination rate constant as calculated in WinNonlin NCA using at least three quantifiable concentrations. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)

    Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.

  17. Pharmacokinetics: Volume of Distribution at Steady State (Vss)

    This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Vss will be calculated as the clearance multiplied with the mean residence time. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)

    Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.

07

Results

Posted Aug 31, 2017

Participant flow

Enrollment was conducted at 14 study sites in 10 countries (USA, Australia, Taiwan, Germany, Russia, Spain, Ukraine, United Kingdom, Italy, Turkey).

Participant flow — Overall Study
MilestoneRecombinant Von Willebrand Factor (rVWF)
Started15
Completed14
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryOverall Hemostatic Efficacy as Assessed by the Investigator (Hemophilia Physician)

Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intra-, and postoperative hemostasis achieved with rVWF with our without ADVATE was as good or better than that expected for the type of surgical procedure performed in a hemostatically normal subject. Good: Intra-, and postoperative hemostasis achieved with rVWF with or without ADVATE was probably as good as that expected for the type of surgical procedure performed in a hemostatically normal subject. Moderate: Intra-, and postoperative hemostasis with rVWF with or without ADVATE was clearly less than optimal for the type of procedure performed but was maintained without the need to change the rVWF concentrate. None: Participant experienced uncontrolled bleeding that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of rVWF concentrate.

Time frame:
24 hours after last peri-operative infusion or at completion of Day 14 (± 2 days) visit, whichever occurs earlier
Reported as:
Count of participants · Participants
Overall Hemostatic Efficacy as Assessed by the Investigator (Hemophilia Physician)
ParticipantsRecombinant Von Willebrand Factor (rVWF)Minor SurgeryMajor SurgeryOral SurgeryVon Willebrand Disease Type 1Von Willebrand Disease Type 2AVon Willebrand Disease Type 2BVon Willebrand Disease Type 2MVon Willebrand Disease Type 3
Excellent1147021107
Good403111011
Moderate000000000
None000000000
SecondaryIntraoperative Actual Versus Predicted Blood Loss as Assessed by the Operating Surgeon

The predicted blood loss will be estimated preoperatively by the operating surgeon based on a hemostatically normal individual of the same sex, age, stature and co-morbidities as the participant. The actual blood loss will be assessed consisting of the estimated blood loss, including into swabs, towels and suction during the procedure, per the anesthesiologist's record.

Time frame:
Day 0 (at completion of surgery)
Reported as:
Mean · mL
Intraoperative Actual Versus Predicted Blood Loss as Assessed by the Operating Surgeon
mLRecombinant Von Willebrand Factor (rVWF)Minor SurgeryMajor SurgeryOral SurgeryVon Willebrand Disease Type 1Von Willebrand Disease Type 2AVon Willebrand Disease Type 2BVon Willebrand Disease Type 2MVon Willebrand Disease Type 3
Actual blood loss94.3 ± 177.880.0 ± 0.00127.0 ± 209.27145.0 ± NA115.0 ± 103.3242.5 ± 53.0350.0 ± NA50.0 ± NA110.6 ± 240.87
Predicted blood loss106.1 ± 161.822.5 ± 5.00152.8 ± 186.33100.0 ± NA100.0 ± 100.0010.0 ± NA50.0 ± NA50.0 ± NA134.4 ± 206.46
SecondaryIntraoperative Actual Blood Loss Relative to Predicted Blood Loss

Actual blood loss relative to predicted blood loss will be calculated as \[Actual Blood loss (mL)\] divided by \[Predicted Blood Loss (mL) multiplied by 100.

Time frame:
Day 0 (at completion of surgery)
Reported as:
Mean · Percent
Intraoperative Actual Blood Loss Relative to Predicted Blood Loss
PercentRecombinant Von Willebrand Factor (rVWF)Minor SurgeryMajor SurgeryOral SurgeryVon Willebrand Disease Type 1Von Willebrand Disease Type 2AVon Willebrand Disease Type 2BVon Willebrand Disease Type 2MVon Willebrand Disease Type 3
Intraoperative Actual Blood Loss Relative to Predicted Blood Loss69.6 ± 44.770.0 ± NA68.9 ± 34.48145.0 ± NA122.5 ± 31.8250.0 ± NA100.0 ± NA100.0 ± NA45.0 ± 38.92
SecondaryIntraoperative Actual Versus Predicted Blood Loss Score as Assessed by the Operating Surgeon

Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intraoperative blood loss was less than or equal to the maximum blood loss expected for the type of procedure performed in a hemostatically normal subject (≤ 100%). Good: Intraoperative blood loss was up to 50% more than the maximum expected blood loss for the type of procedure performed in a hemostatically normal subject (101-150%) Moderate: Intraoperative blood loss was more than 50% of the maximum expected blood loss for the type of procedure performed in a hemostatically normal subject (\>150%). None: Uncontrolled hemorrhage that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of clotting factor replacement regimen.

Time frame:
Day 0 (at completion of surgery)
Reported as:
Count of participants · Participants
Intraoperative Actual Versus Predicted Blood Loss Score as Assessed by the Operating Surgeon
ParticipantsRecombinant Von Willebrand Factor (rVWF)Minor SurgeryMajor SurgeryOral SurgeryVon Willebrand Disease Type 1Von Willebrand Disease Type 2AVon Willebrand Disease Type 2BVon Willebrand Disease Type 2MVon Willebrand Disease Type 3
Excellent1348131117
Good202001001
Moderate000000000
None000000000
SecondaryIntraoperative Hemostatic Efficacy Score as Assessed by the Operating Surgeon

Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intraoperative hemostasis achieved with rVWF with our without ADVATE was as good or better than that expected for the type of surgical procedure performed in a hemostatically normal subject. Good: Intraoperative hemostasis achieved with rVWF with or without ADVATE was probably as good as that expected for the type of surgical procedure performed in a hemostatically normal subject. Moderate: Intraoperative hemostasis with rVWF with or without ADVATE was clearly less than optimal for the type of procedure performed but was maintained without the need to change the rVWF concentrate. None: Participant experienced uncontrolled bleeding that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of rVWF concentrate.

Time frame:
Day 0 (at completion of surgery)
Reported as:
Count of participants · Participants
Intraoperative Hemostatic Efficacy Score as Assessed by the Operating Surgeon
ParticipantsRecombinant Von Willebrand Factor (rVWF)Minor SurgeryMajor SurgeryOral SurgeryVon Willebrand Disease Type 1Von Willebrand Disease Type 2AVon Willebrand Disease Type 2BVon Willebrand Disease Type 2MVon Willebrand Disease Type 3
Excellent1348131117
Good202001001
Moderate000000000
None000000000
SecondaryDaily Intra- and Postoperative Weight-adjusted Dose of rVWF With or Without ADVATE
Time frame:
Daily, from day of surgery through postoperative Day 14 (± 2 days)
Reported as:
Median · IU/kg
Daily Intra- and Postoperative Weight-adjusted Dose of rVWF With or Without ADVATE
IU/kgRecombinant Von Willebrand Factor (rVWF)
intraoperative18.1 (18.1 to 18.1)
postoperative day 123.5 (16.9 to 47.2)
postoperative day 242.3 (23.2 to 50.6)
postoperative day 328.6 (20.6 to 48.9)
postoperative day 433.9 (23.2 to 44.3)
postoperative day 531.5 (18.8 to 47.2)
postoperative day 623.2 (18.8 to 23.6)
postoperative day 723.8 (23.6 to 50.8)
postoperative day 833.9 (23.6 to 53.6)
postoperative day 923.6 (16.3 to 53.6)
postoperative day 1023.6 (16.3 to 34.8)
postoperative day 1123.6 (16.3 to 53.6)
postoperative day 1229.3 (20.1 to 44.2)
postoperative day 1316.3 (16.3 to 16.3)
postoperative day 1425.5 (16.3 to 34.8)
postoperative day 1516.3 (16.3 to 16.3)
SecondaryOccurrence of Adverse Events

Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated.

Time frame:
From first infusion of investigational product through study completion (ie, 14 (± 2) days post surgery)
Reported as:
Number · Adverse Events
Occurrence of Adverse Events
Adverse EventsRecombinant Von Willebrand Factor (rVWF)
Treatment emergent Adverse Events (TEAEs)12
Severe TEAEs1
TEAEs related to rVWF0
TEAEs related to ADVATE0
TEAEs related to both rVWF and ADVATE0
Treatment emergent Serious Adverse Events (TESAEs)2
TESAEs related to rVWF0
TESAEs related to ADVATE0
TESAEs related to both rVWF and ADVATE0
TEAEs leading to discontinuation of rVWF0
TEAEs leading to discontinuation of ADVATE0
TEAEs leading to discontinuation of study0
TEAEs leading to death0
TEAEs related to study procedure0
TESAEs related to study procedure0
SecondaryOccurrence of Thrombotic Events

Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated for thrombotic events.

Time frame:
From first infusion of investigational product through study completion (ie, 14 (± 2) days post surgery)
Reported as:
Number · Adverse Events
Occurrence of Thrombotic Events
Adverse EventsRecombinant Von Willebrand Factor (rVWF)
Thrombotic TEAEs2
Thrombotic TESAEs1
SecondaryOccurrence of Severe Allergic Reactions (eg, Anaphylaxis)

Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated for severe allergic reactions.

Time frame:
From first infusion of investigational product through study completion (ie, 14 (± 2) days post surgery)
Reported as:
Number · Adverse Events
Occurrence of Severe Allergic Reactions (eg, Anaphylaxis)
Adverse EventsRecombinant Von Willebrand Factor (rVWF)
Severe allergic reaction TEAEs0
Severe allergic reaction TESAEs0
SecondaryNumber of Participants Who Developed Inhibitory and Total Binding Antibodies to Von Willebrand Factor (VWF) and Inhibitory Antibodies to Factor VIII (FVIII)

Participants were treated with recombinant van Willebrand Factor (rVWF) with or without ADVATE.

Time frame:
Testing occurred throughout the study at screening, prior PK infusion, pre-surgery, post surgery in case of excessive bleeding or unexplained bleeding, at postoperative day 7 and at study completion visit (ie. 14 (± 2) days post surgery).
Reported as:
Count of participants · Participants
Number of Participants Who Developed Inhibitory and Total Binding Antibodies to Von Willebrand Factor (VWF) and Inhibitory Antibodies to Factor VIII (FVIII)
ParticipantsRecombinant Von Willebrand Factor (rVWF)
Development of inhibitory antibodies to VWF0
Development of total binding antibodies to VWF1
Development of inhibitory antibodies to FVIII0
SecondaryNumber of Participants Who Developed Antibodies to Chinese Hamster Ovary (CHO) Proteins, Mouse Immunoglobulin G (IgG) or Recombinant Furin (rFurin)

Participants were treated with recombinant van Willebrand Factor (rVWF) with or without ADVATE.

Time frame:
Testing occurred throughout the study at screening, prior PK infusion, pre-surgery, post surgery in case of excessive bleeding or unexplained bleeding, at postoperative day 7 and at study completion visit (ie. 14 (± 2) days post surgery).
Reported as:
Count of participants · Participants
Number of Participants Who Developed Antibodies to Chinese Hamster Ovary (CHO) Proteins, Mouse Immunoglobulin G (IgG) or Recombinant Furin (rFurin)
ParticipantsRecombinant Von Willebrand Factor (rVWF)
Number of Participants Who Developed Antibodies to Chinese Hamster Ovary (CHO) Proteins, Mouse Immunoglobulin G (IgG) or Recombinant Furin (rFurin)0
SecondaryPharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Post-infusion (AUC 0-72 h/Dose)

This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. The area under the plasma concentration/time curve from 0 to 72 hours post-infusion will be computed using the linear trapezoidal rule. For the calculation of AUC(0-72h) the levels at 72 hours will be linearly interpolated/extrapolated from the 2 nearest sampling time points. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac), FVIII Coagulation Activity (FVIII:C)

Time frame:
PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Reported as:
Geometric mean · hours*IU/dL
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Post-infusion (AUC 0-72 h/Dose)
hours*IU/dLRecombinant Von Willebrand Factor (rVWF)
VWF:RCo31.91 ± 37.5
VWF:Ag57.08 ± 25.6
VWF:CB63.91 ± 29.4
VWF:Ac54.61 ± 28.1
FVIII:C67.49 ± 31.1
SecondaryPharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC 0-∞ /Dose)

This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. The area under the plasma concentration/time curve from time 0 to infinity and the area under the first moment curve from time 0 to infinity will be calculated as the sum of AUC or AUMC from time 0 to the time of last quantifiable concentration plus a tail area correction calculated as Ct/λz and Ct/λz(t+1/λz), respectively, where Ct is the last quantifiable concentration, t is the time of last quantifiable concentration and λz is the terminal or disposition rate constant. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac), FVIII Coagulation Activity (FVIII:C)

Time frame:
PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Reported as:
Geometric mean · hours*IU/dL
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC 0-∞ /Dose)
hours*IU/dLRecombinant Von Willebrand Factor (rVWF)
VWF:RCo34.43 ± 43.3
VWF:Ag68.87 ± 31.5
VWF:CB71.82 ± 34.1
VWF:Ac61.90 ± 32.2
FVIII:C75.00 ± 30.9
SecondaryPharmacokinetics: Mean Residence Time (MRT)

This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Mean residence time will be calculated as area under the first moment curve from time 0 to infinity divided by the area under the curve time 0 to infinity minus T/2 where T is the duration of the infusion. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)

Time frame:
PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Reported as:
Geometric mean · hours
Pharmacokinetics: Mean Residence Time (MRT)
hoursRecombinant Von Willebrand Factor (rVWF)
VWF:RCo22.69 ± 41.3
VWF:Ag37.92 ± 28.4
VWF:CB29.35 ± 31.1
VWF:Ac29.75 ± 28.6
SecondaryPharmacokinetics: Clearance (CL)

This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Clearance will be calculated as dose (IU/kg) divided by the area under the curve time 0 to infinity. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)

Time frame:
PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Reported as:
Geometric mean · dL/hour/kg
Pharmacokinetics: Clearance (CL)
dL/hour/kgRecombinant Von Willebrand Factor (rVWF)
VWF:RCo0.02904 ± 43.3
VWF:Ag0.01452 ± 31.5
VWF:CB0.01392 ± 34.1
VWF:Ac0.01616 ± 32.2
SecondaryPharmacokinetics: Incremental Recovery (IR)

This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Incremental recovery will be calculated as (Cmax minus Cpreinfusion) divided by the dose (IU/kg) where kg refers to the body weight at the time of dosing and Cmax is the observed maximum concentration before correction for pre-infusion values. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)

Time frame:
PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Reported as:
Mean · IU/dL
Pharmacokinetics: Incremental Recovery (IR)
IU/dLRecombinant Von Willebrand Factor (rVWF)
VWF:RCo1.961 ± 0.45445
VWF:Ag1.991 ± 0.38395
VWF:CB2.780 ± 0.56640
VWF:Ac2.635 ± 0.38050
SecondaryPharmacokinetics: Elimination Phase Half-life (T1/2)

This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Terminal or disposition half-life (T1/2) will be calculated as ln2/λz where λz is the terminal elimination rate constant as calculated in WinNonlin NCA using at least three quantifiable concentrations. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)

Time frame:
PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Reported as:
Geometric mean · hours
Pharmacokinetics: Elimination Phase Half-life (T1/2)
hoursRecombinant Von Willebrand Factor (rVWF)
VWF:RCo16.52 ± 42.7
VWF:Ag26.88 ± 26.5
VWF:CB21.07 ± 33.2
VWF:Ac22.19 ± 28.5
SecondaryPharmacokinetics: Volume of Distribution at Steady State (Vss)

This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Vss will be calculated as the clearance multiplied with the mean residence time. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)

Time frame:
PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Reported as:
Geometric mean · dL/kg
Pharmacokinetics: Volume of Distribution at Steady State (Vss)
dL/kgRecombinant Von Willebrand Factor (rVWF)
VWF:RCo0.6591 ± 28.8
VWF:Ag0.5506 ± 18.4
VWF:CB0.4086 ± 24.0
VWF:Ac0.4806 ± 21.5

Adverse events

Collected over Throughout the study period (from the first exposure to investigational product until study completion or discontinuation date). Total study duration: 1 year and 3 months. Per participant: up to 58 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Recombinant Von Willebrand Factor (rVWF)0/15 (0%)2/15 (13.3%)6/15 (40%)
Most frequent serious events
Most frequent serious events
EventRecombinant Von Willebrand Factor (rVWF)
DiverticulitisInfections and infestations1/15
Deep vein thrombosisVascular disorders1/15
Most frequent other events
Most frequent other events
EventRecombinant Von Willebrand Factor (rVWF)
AcneSkin and subcutaneous tissue disorders1/15
Dry skinSkin and subcutaneous tissue disorders1/15
Iron deficiency anaemiaBlood and lymphatic system disorders1/15
Peripheral swellingGeneral disorders1/15
NasopharyngitisInfections and infestations1/15
Joint swellingMusculoskeletal and connective tissue disorders1/15
DizzinessNervous system disorders1/15
HeadacheNervous system disorders1/15
Pelvic painReproductive system and breast disorders1/15
Deep vein thrombosisVascular disorders1/15

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Recombinant Von Willebrand Factor (rVWF)
Median40.0 (20.0 to 70.0)
Sex: Female, Male
Sex: Female, Male(Participants)Recombinant Von Willebrand Factor (rVWF)
Female8
Male7
08

Study locations

34 sites
  • University of Colorado Hemophilia & Thrombosis Center
    Aurora, Colorado 80045, United States
  • University of Miami, Jackson Memorial Hospital
    Miami, Florida 33136, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • John Hopkins University
    Baltimore, Maryland 21205, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Rutgers - Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Case Western Reserve University Hospital
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Blood Center of South East Wisconsin
    Milwaukee, Wisconsin 53233, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • The Perth Blood Institute
    Nedlands, Western Australia 6009, Australia
  • Fiona Stanley Hospital
    Perth, Western Australia 6000, Australia
  • AKH - Medizinische Universität Wien
    Vienna, 1090, Austria
  • Fakultni nemocnice Ostrava
    Ostrava, 70852, Czechia
  • Universitätsmedizin der Johannes Gutenberg Universität Mainz
    Mainz, Rheinland-Pfalz 55101, Germany
  • Azienda Ospedaliero - Universitaria Careggi
    Firenze (Florence), 50139, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • Umberto I Policlinico di Roma, Universitá di Roma La Sapienza
    Rome, 00144, Italy
  • Erasmus Medisch Centrum
    Rotterdam, 3015 CE, Netherlands
  • Regional Budgetary State Healthcare Institution (SHI) "Regional Clinical Hospital"
    Barnaul, 656024, Russian Federation
  • FSI Kirov Institute of Hematology and Blood Transfusion FMBA
    Kirov, 610027, Russian Federation
  • Complejo Hospitalario Universitario A Coruña
    A Coruña, 15006, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, 46026, Spain
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • Tri-Service General Hospital
    Taipei, 10002, Taiwan
  • National Taiwan University Hospital
    Taipei, 11490, Taiwan
  • Ege University Medical Faculty
    Izmir, 35100, Turkey
  • SI Institute of Blood Pathology and Transfusion Medicine of NAMSU
    Lviv, 79044, Ukraine
  • Derriford Hospital
    Plymouth, Devon PL6 8DH, United Kingdom
  • Royal Free Hospital
    London, Greater London NW3 2QG, United Kingdom
  • Churchill Hospital
    Oxford, Oxfordshire OX3 7LJ, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Jul 2016, 15 months.

Results were first posted in Aug 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2014
First posted
Nov 5, 2014
StartActual
Apr 1, 2015
Primary completionActual
Jul 6, 2016
CompletionActual
Jul 6, 2016
Results first posted
Aug 31, 2017
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02283268
Responsible party
Sponsor
First posted
Nov 5, 2014
Start date
Apr 1, 2015
Primary completion
Jul 6, 2016
Completion
Jul 6, 2016
Results posted
Aug 31, 2017
Last update
May 19, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonicog alfa

Start the discussion